Educational Symposium
Cytokines and IgA Nephropathy: Pathogenesis and Novel Therapies
November 04, 2023 | 12:45 PM - 01:45 PM
Location: Grand Ballroom Salon A, Level 5, Philadelphia Marriott Downtown
Session Description
Despite remaining the most common primary glomerulonephritis worldwide, there are very few treatment options for IgA nephropathy (IgAN). The US Food and Drug Administration recently approved novel immunosuppressive and nonimmunosuppressive therapies for IgAN, and there are many more targeted therapeutic options on the horizon.
The "four-hit hypothesis" regarding the pathogenesis of IgAN centers on formation of anti-galactose-deficient IgA1 (Gd-IgA1) antibodies, deposition of the immune complexes in the glomerulus, and subsequent inflammation causing glomerulonephritis. B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are cytokines that maintain the B cell pool. BAFF and APRIL levels are increased in patients with IgAN and correlate with gd-IgA1 levels. Thus, therapies targeting Gd-IgA1 antibody production via BAFF or APRIL may offer a novel treatment option for patients with IgAN.
Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.
Learning Objective(s)
- Explain the significance of BAFF and APRIL in the pathogenesis of IgAN
- Discuss emerging therapies targeting BAFF and APRIL in IgAN
Learning Pathway(s)
- Glomerular Diseases
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Roles of APRIL and BAFF in the Pathogenesis of IgA Nephropathy
12:55 PM - 01:15 PM
- Therapies Targeting BAFF and APRIL in IgA Nephropathy
01:15 PM - 01:35 PM
- Audience Q&A
01:35 PM - 01:45 PM